#ACAAI25: BW-20805 safely and significantly reduced levels of #PlasmaPrekallikrein for up to 24 weeks after a single dose in healthy volunteers, supporting its potential as a long-acting preventive therapy for #HereditaryAngioedema (HAE)
Read here: https://bit.ly/3Jt4YFs
#RareDisease #BW20805 #HAE
Read here: https://bit.ly/3Jt4YFs
#RareDisease #BW20805 #HAE
BW-20805 Sustains Prekallikrein Suppression in Phase 1 HAE Trial
Mean maximum reductions of prekallikrein from baseline were 75% at 50 mg, 87% at 150 mg, 94% at 300 mg, and 95% at 600 mg.
bit.ly
November 8, 2025 at 8:30 PM
#ACAAI25: BW-20805 safely and significantly reduced levels of #PlasmaPrekallikrein for up to 24 weeks after a single dose in healthy volunteers, supporting its potential as a long-acting preventive therapy for #HereditaryAngioedema (HAE)
Read here: https://bit.ly/3Jt4YFs
#RareDisease #BW20805 #HAE
Read here: https://bit.ly/3Jt4YFs
#RareDisease #BW20805 #HAE